Portable UTI Molecular Diagnostic Platform Provides Accurate Test Results in 40 Minutes
|
By HospiMedica International staff writers Posted on 09 Nov 2022 |

Despite being one of the most common types of infection Urinary Tract Infections (UTIs) are a comparatively neglected area of medicine. There are no highly accurate diagnostic tools available for point-of-care testing. Currently, the gold standard for UTI diagnosis is to use laboratory culture but this takes at least 24 hours and often involves the transportation of the sample, adding further delay. The absence of fast diagnostic testing means clinicians make treatment decisions based on vague clinical symptoms or inaccurate urine dipstick tests. Now, a rapid and affordable point-of-care molecular diagnostics platform developed specifically to detect bacterial and viral infections aims to change that.
Llusern Scientific Limited’s (Wales, UK) Lodestar DX is a user-friendly, portable molecular platform for testing UTIs and respiratory diseases that provides lab-accurate test results in 30 minutes. The low cost platform technology allows users to conveniently carry out Loop-mediated isothermal amplification (LAMP) reactions. The technique allows amplification and detection of DNA or RNA in a wide range of bacterial and viral targets. Lodestar DX uses an internal algorithm to determine if a LAMP reaction is positive or negative. The algorithm is suitable for use with a wide range of LAMP reactions. The Lodestar DX system outputs the fluorescent reaction data in real time which can be captured directly onto a PC and stored for subsequent off-line analysis. The system can run eight reactions simultaneously and can be operated flexibly based on user needs. It can be operated from the mains supply using its powers adapter or using a 15Vdc source such as a standard vehicle lighter plug, allowing usage in remote settings.
In 2023, Llusern plans to launch a panel of Urinary Tract Infection (UTI) assays including E-coli, Klebsiella and Staphylococcus spp that run on Lodestar DX. Currently undergoing clinical validation, Llusern’s UTI test has a preliminary sensitivity of 95% for E.coli and can detect over 95% of all uropathogens. Easy to use, it does not require sample processing and urine is added directly into the assay tubes for results delivered in 30 minutes. The simple test preparation and ease of use of the Lodestar DX makes it a useful tool in doctor’s offices, clinics and pharmacies. Llusern's molecular diagnostic test for UTIs is a significant step-forward in addressing a huge everyday health problem faced by hundreds of millions of people around the globe.
Related Links:
Llusern Scientific Limited
Latest Point of Care News
Channels
Artificial Intelligence
view channelAI Analysis of Pericardial Fat Refines Long-Term Heart Disease Risk
Accurately identifying long-term cardiovascular disease risk in asymptomatic adults remains challenging for clinicians. Missed or underestimated risk delays preventive therapy and increases the chance... Read more
Machine Learning Approach Enhances Liver Cancer Risk Stratification
Hepatocellular carcinoma, the most common form of primary liver cancer, is often detected late despite targeted surveillance programs. Current screening guidelines emphasize patients with known cirrhosis,... Read moreCritical Care
view channel
Eye Imaging AI Identifies Elevated Cardiovascular Risk
Many adults at risk for atherosclerotic cardiovascular disease are not identified until they undergo formal primary care assessment. Delayed risk recognition can postpone initiation of statins and lifestyle... Read more
Noninvasive Monitoring Device Enables Earlier Intervention in Heart Failure
Hospitalizations for heart failure with preserved ejection fraction (HFpEF) remain common because lung congestion often worsens before symptoms prompt treatment changes. Missed early decompensation... Read moreSurgical Techniques
view channel
Fiber-Form Bone Graft Expands Intraoperative Options for Spinal Fusion
Spinal and orthopedic fusion procedures often require bone graft materials that handle predictably and support bone formation. Surgeons face added complexity in difficult anatomy and challenging fusion environments.... Read more
Ultrasound‑Aided Catheter Treatment Cuts Early Collapse in Pulmonary Embolism
Acute pulmonary embolism can cause rapid hemodynamic deterioration and early death in hospitalized and emergency patients. Systemic thrombolysis can dissolve clots but is limited by a high risk of major... Read morePatient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read moreHealth IT
view channel
Voice-Driven AI System Enables Structured GI Procedure Documentation
Documentation during gastrointestinal (GI) procedures often competes with real-time clinical decision-making and imposes a significant cognitive burden on physicians. Manual data entry and post-procedure... Read more
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read moreBusiness
view channel







